Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings

被引:69
|
作者
Krawczyk, Noa [1 ]
Williams, Arthur Robin [2 ]
Saloner, Brendan [3 ]
Cerda, Magdalena [1 ]
机构
[1] NYU, Grossman Sch Med, Dept Populat Hlth, Room 4-12,180 Madison Ave, New York, NY 10003 USA
[2] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10027 USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
关键词
Medication treatment; Opioid use disorder; Retention; Discontinuation; Overdose; METHADONE-MAINTENANCE TREATMENT; BUPRENORPHINE TREATMENT; UNITED-STATES; RETENTION; DISCONTINUATION; DEPENDENCE; OUTCOMES; RELEASE; PROGRAM; METAANALYSIS;
D O I
10.1016/j.jsat.2021.108329
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings. Methods: We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models. Results: Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76). Conclusions: Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [31] The NP and medication-assisted treatment for opioid use disorder
    Warner, Shirley A.
    Strickland, Daniel M.
    NURSE PRACTITIONER, 2022, 47 (07): : 10 - 13
  • [32] Addressing Stigma in Medication Treatment of Adolescents With Opioid Use Disorder
    Bagley, Sarah M.
    Hadland, Scott E.
    Carney, Brittany L.
    Saitz, Richard
    JOURNAL OF ADDICTION MEDICINE, 2017, 11 (06) : 415 - 416
  • [33] Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment SettingsHarm Reduction in Outpatient Addiction Treatment
    Jessica L. Taylor
    Samantha Johnson
    Ricardo Cruz
    Jessica R. Gray
    Davida Schiff
    Sarah M. Bagley
    Journal of General Internal Medicine, 2021, 36 : 3810 - 3819
  • [34] ALCOHOL AND ILLICIT SUBSTANCE USE IMPACT TREATMENT OUTCOMES AMONG PATIENTS RECEIVING OUTPATIENT MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER
    Van Dyke, N.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 45 : 134A - 134A
  • [35] Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study
    Emily G. Hichborn
    Owen B. Murray
    Eilis I. Murphy
    Tess E. Gallant
    Sarah K. Moore
    Bethany M. McLeman
    John Saroyan
    Anthony Folland
    Megan Mitchell
    Lisa A. Marsch
    Addiction Science & Clinical Practice, 20 (1)
  • [36] Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention
    Ray-Griffith, Shona
    Tharp, Emily
    Coker, Jessica L.
    Catlin, David
    Knight, Bettina
    Stowe, Zachary N.
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (01): : 43 - 48
  • [37] Rationale, evidence, and steps for implementation of medication for opioid use disorder treatment programs in HIV primary care settings
    Brizzi, Marisa
    Green, Sarah B. B.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2023, 35 (11): : 1760 - 1767
  • [38] Patient Activation of Persons With Opioid Use Disorder in Intensive Outpatient Treatment
    Keen, Alyson
    Lu, Yvonne
    Oruche, Ukamaka M.
    Mazurenko, Olena
    Draucker, Claire Burke
    JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION, 2024, 30 (02) : 333 - 342
  • [39] A Pilot Study to Assess Breastfeeding Knowledge, Attitudes, and Perceptions of Individuals Who Work in Perinatal Opioid Use Disorder Treatment Settings
    Short, Vanessa L.
    Cambareri, Katherine
    Gannon, Meghan
    Alexander, Karen
    Abatemarco, Diane J.
    BREASTFEEDING MEDICINE, 2019, 14 (05) : 307 - 312
  • [40] Weight change in a national cohort of US Military Veterans engaged in medication treatment for opioid use disorder
    Carr, Meagan M.
    Wolkowicz, Noah R.
    Cave, Shayna
    Martino, Steve
    Masheb, Robin
    Midboe, Amanda M.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2023, 168 : 204 - 212